For the sample under analysis, total savings gained by generic entry amounted to at least € 14 billion over the period.
Vaatlusaluse valimi puhul ulatus geneerilise ravimi turuletulekuga seotud kokkuhoid kõnealuses ajavahemikus vähemalt 14 miljardi euroni.